Hope E. Uronis

Duke University — United States

Medicine · Health Sciences

29h-index5.4kcitations668works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(45), Colorectal Cancer Treatments and Studies(41), Pancreatic and Hepatic Oncology Research(32), Cancer Treatment and Pharmacology(28), Esophageal Cancer Research and Treatment(24)

Publications161 total

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago‐gastric Diseases (PROCEED): A single‐arm phase 2 trial
Cancer·2025
Tumor <i>NLRP3</i> Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression
2025Open Access
ASO Visual Abstract: ctDNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
Annals of Surgical Oncology·2025
ASO Author Reflections: Towards Personalized Cancer Therapy: The Role of ctDNA as a Biomarker in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
Annals of Surgical Oncology·2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
Nature Communications·2025· 2 citedOpen Access
Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
Annals of Surgical Oncology·2025· 2 cited
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
Journal of Clinical Oncology·2025· 22 cited
Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective
Annals of Surgical Oncology·2025· 3 cited
Phase Ib/ <scp>II</scp> study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors ( <scp>PLANET</scp> )
Journal of Neuroendocrinology·2025· 4 citedOpen Access
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma
Annals of Surgical Oncology·2025
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma
Annals of Surgical Oncology·2025· 5 cited
ASO Visual Abstract: Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding Hai Program
Annals of Surgical Oncology·2025
Hepatic Arterial Infusion Team Site Visit
2025
Ultra-sensitive, tumor-informed ctDNA profiling in pembrolizumab-treated esophagogastric cancer patients predicts clinical responses
2024Open Access
ASO Author Reflections: Expansion of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Colorectal Liver Metastases
Annals of Surgical Oncology·2024
Author response for "Phase Ib/&lt;scp&gt;II&lt;/scp&gt; study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (&lt;scp&gt;PLANET&lt;/scp&gt;)"
2024
Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program
Annals of Surgical Oncology·2024· 8 cited
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
Journal of Clinical Oncology·2024· 22 citedOpen Access
Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.
Journal of Clinical Oncology·2024· 1 cited
Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2–negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy.
Journal of Clinical Oncology·2024
page 1 of 9Next →

Frequent Co-authors

Herbert I. Hurwitz(17), S. Yousuf Zafar(14), Michael A. Morse(11), Johanna C. Bendell(9), Gerard C. Blobe(9), Andrew B. Nixon(9), Ronan J. Kelly(7), Shiaowen David Hsu(7), Kellen L. Meadows(7), Jaffer A. Ajani(6), Amy P. Abernethy(6), Brian G. Czito(6), Christopher G. Willett(6), Herbert Pang(6), John H. Strickler(6), James M. Cleary(5), Manisha Palta(5), Christel Rushing(5), Jarosław Kużdżał(4), Thomas Zander(4)